GO
Loading...

Allergan, Valeant perfect match: CEO

Tuesday, 22 Apr 2014 | 10:48 AM ET

CNBC's David Faber and Jeffrey Ubben, ValueAct Capital Partners CEO, discuss Valeant Pharmaceuticals bid for Allergan and why Valeant needed investor Bill Ackman involved in the deal.